Dianthus price target raised to $51 from $34 at Raymond James

Raymond James analyst Steven Seedhouse raised the firm’s price target on Dianthus (DNTH) to $51 from $34 and keeps an Outperform rating on the shares. Updated data from Sanofi’s (SNY) C1s inhibitor, riliprubart, provides proof of mechanism for aC1s in a broad CIDP population derisk DNTH103 enough in Chronic Inflammatory Demyelinating Polyneuropathy to add CIDP to the firm’s model, the analyst tells investors in a research note.